Treatment of vaginal atrophy using fractional micro ablative carbon dioxide (CO2) laser in post-menopausal women with breast cancer on aromatase inhibitors: a pilot study
Not Applicable
Not yet recruiting
- Conditions
- Breast cancerGenitourinary syndrome of MenopauseVulval-vaginal atrophy
- Registration Number
- ACTRN12617000287336
- Lead Sponsor
- Australia and New Zealand Breast Cancer Trials Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- Female
- Target Recruitment
- 36
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie fractional CO2 laser therapy for vulval-vaginal atrophy in breast cancer patients on aromatase inhibitors?
How does fractional microablative CO2 laser compare to standard-of-care treatments for genitourinary syndrome of menopause in post-menopausal breast cancer patients?
What biomarkers are associated with response to fractional CO2 laser therapy in post-menopausal women with breast cancer on aromatase inhibitors?
What are the known adverse events and management strategies for fractional CO2 laser treatment in post-menopausal breast cancer patients with vaginal atrophy?
Are there any combination approaches or competitor drugs being evaluated alongside fractional CO2 laser for treating aromatase inhibitor-induced genitourinary syndrome of menopause?